ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced it has expanded its cooperation agreement with Brainlab, an innovation leader with an expansive and diversified spine imaging, planning, and navigation portfolio, as well as robotic imaging, surgical assistance, and mixed reality to support spinal surgeries.
ZimVie and Brainlab have started a joint project to achieve compatibility between ZimVie’s Vital and Virage fixation systems and Brainlab spine and trauma navigation technologies, which help surgeons plan and execute spinal procedures, accurately place pedicle screws, and minimize radiation exposure. In addition, ZimVie will co-market the Brainlab spine and trauma navigation technologies alongside its existing spine implant solutions globally.
“We are excited to partner with Brainlab to bring into the operating room differentiated technology aiming at enhancing workflow and accuracy for surgeons and staff,” said Vafa Jamali, President and Chief Executive Officer of ZimVie. “We have been focused on expanding our portfolio with enabling technology to drive greater adoption across our spine portfolio. Our common interest in delivering clinical and economic value to our customers and patients aligns perfectly with ZimVie’s strategic initiatives.”
“As the provider of an advanced portfolio of spine enabling technologies in the market, Brainlab is an ideal partner in our mission to make spine surgery more efficient and reproducible without compromising accuracy and safety,” said Rebecca Whitney, President of Global Spine at ZimVie. “Additionally, we will benefit from a complementary customer base with little overlap in existing accounts. The introduction of the Brainlab portfolio of enabling technologies to ZimVie surgeon customers represents potential upside for both companies and helps us to make an impact on the lives of physicians and patients.”
For more information on ZimVie Spine solutions for restorative procedures, please visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version